KR-39038
Based on 1 publication(s) in Google Scholar
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 2770300-35-9
- Formula: C24H32ClFN6O
- Molecular Weight:475.00
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) KR-39038
More
Biological Activity
|
HDAC5 |
KR-39038 (0-1.0 μM, 24 h) significantly inhibits angiotensin II-induced cellular hypertrophy and HDAC5 phosphorylation in neonatal cardiomyocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary neonatal cardiomyocytes (isolated from S.D. rats (1-2 days old) using primary myocardial cell isolation kit)
-
Concentration:0 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1.0 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited angiotensin II-induced cellular hypertrophy at a concentration of 0.1 µM and higher concentrations. Decreased angiotensin II-induced HDAC5 phosphorylation at 0.3 µM and higher concentrations.
Pharmacokinetic Parameters of KR-39038 in Sprague-Dawley rats[1].
| Parameters | IV (5 mg/kg) | PO (300 mg/kg) |
| Cmax (µg/mL) | NA | 5.2 ± 2.8 |
| Tmax (h) | NA | 0.7 ± 0.2 |
| t1/2 (h) | 0.7 ± 0.04 | 2.3 ± 2.9 |
| AUC0-∞ (µg*h/mL) | 3.4 ± 1.0 | 8.9 ± 5.0 |
| CL (L/h/kg) | 1.6 ± 0.5 | NA |
| Vss (L/kg) | 1.2 ± 0.2 | NA |
| F (%) | 4.3 ± 2.4 |